What is Melanotan II?
Melanotan II (MT-2) is a synthetic analog of the alpha-melanocyte-stimulating hormone (α-MSH), developed to study melanocortin receptor activity. In laboratory settings, it is widely used in research exploring pigmentation, sexual function, appetite regulation, and neurobehavioral responses. It binds primarily to MC1R, MC3R, MC4R, and MC5R, making it a versatile tool in studies involving melanocortin signaling pathways. Due to its broad receptor interaction profile, it is currently being evaluated in preclinical studies involving metabolic regulation, mood disorders, and skin pigmentation.
Melanotan II is a synthetic peptide designed to mimic the natural hormone α-MSH. It has been extensively studied for its impact on melanogenesis (skin pigmentation), sexual behavior, and appetite suppression. Research indicates that it acts on multiple melanocortin receptors, offering insights into a variety of physiological and neurological functions. It is provided in lyophilized powder form for research applications and is not intended for human or veterinary use.
Structure
- Chemical formula: C50H69N15O9
Melanotan II is a cyclic heptapeptide that contains a lactam bridge and functions as a non-selective agonist of melanocortin receptors, enhancing stability and receptor affinity in experimental conditions.
Melanotan II Research
Melanocortin Signaling
Melanotan II is a key research peptide for studying the melanocortin system, particularly MC1R through MC5R. Studies suggest it enhances melanogenesis by binding to MC1R on melanocytes, stimulating the production of eumelanin. Additionally, its effects on MC3R and MC4R are being explored for their influence on energy balance, sexual function, and behavior. It continues to provide a valuable platform for understanding how melanocortin signaling affects systemic physiology in preclinical models [1].
Autism
Some animal studies have suggested that melanocortin receptor activity could influence social and behavioral patterns associated with autism spectrum disorder (ASD). It has been investigated for its effects on repetitive behaviors and social interaction in rodent models. Early research indicates a potential role in modulating neuropeptides linked to behavior and stress, though these findings remain preliminary and require further investigation to establish translational relevance [2].
Hunger
Melanotan II has demonstrated appetite-suppressing effects in rodent models, particularly through its action on the MC4R receptor. Research indicates that it may reduce food intake and increase energy expenditure by influencing central pathways involved in hunger and satiety. These findings make it an important compound in the study of obesity, metabolic disorders, and appetite regulation at the molecular level [3].
Diabetes
Preclinical trials have explored its ability to improve insulin sensitivity and reduce body weight in diabetic models. Its effects on glucose metabolism may be attributed to interactions with MC4R, which is known to play a role in energy homeostasis. Although it is not a therapeutic agent, research is ongoing to evaluate its implications in understanding and potentially addressing metabolic dysfunction in diabetes [4].
Impulse Control and Alcohol Intake
Studies have investigated the role of Melanotan II in regulating impulsive behaviors, including alcohol consumption. It appears to modulate dopaminergic pathways associated with reward and compulsion, making it a potential research compound in studies focused on addiction and self-regulation. Its influence on MC4R may be key in altering neural circuits related to impulse control and substance use [5].
Erectile Dysfunction
Melanotan II has shown promise in animal models for its ability to induce spontaneous erections by activating the MC3R and MC4R receptors in the central nervous system. These studies suggest a mechanism independent of traditional nitric oxide pathways, making it a novel compound for investigating sexual function and potential non-hormonal treatments for erectile dysfunction in research settings [6]. Notably, a structurally related melanocortin agonist, bremelanotide (PT-141), advanced to FDA approval as Vyleesi, underscoring the therapeutic interest in this receptor pathway.
Future Research
Emerging research is expanding its profile into areas such as mood regulation, neuroinflammation, and neurodegenerative conditions. Scientists are particularly interested in its potential to influence brain-derived neurotrophic factors (BDNF), inflammation markers, and behavioral adaptations. As understanding of the melanocortin system grows, Melanotan II remains a critical tool in mapping physiological and psychological processes tied to receptor signaling [7].
Reconstitution and dosing
Melanotan II is typically reconstituted with Bacteriostatic water at 10mg per ml. Dosing can vary largely depending on which aspect of its benefits are of primary concern. Standard dosing can start as low as 25mcg for sexual health up to 500mcg for pigmentation. Dosing can titrate up to achieve satisfactory results, followed by maintenance dosing to maintain pigmentation.
For our free Peptide Calculator, CLICK HERE. Research-grade Melanotan II is available from WellnessPeptides.
Referenced Citations
- Dorr RT, Ertl G, Levine N, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci. 1996. https://pubmed.ncbi.nlm.nih.gov/8637402/
- Minakova E, Lang J, Medel-Matus JS, et al. “Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism.” PLoS One. 2019;14(1):e0210389. https://pubmed.ncbi.nlm.nih.gov/30629642/
- Rios-Ruano M, et al. “Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food.” Pharmacol Biochem Behav. 2022. https://pubmed.ncbi.nlm.nih.gov/36155088/
- Heijboer AC, van den Hoek AM, Pijl H, et al. “The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats.” Peptides. 2004. https://pubmed.ncbi.nlm.nih.gov/15350695/
- Navarro M, Cubero I, Thiele TE, et al. “Effects of melanocortin receptor activation and blockade on ethanol intake: a possible role for the melanocortin-4 receptor.” Alcohol Clin Exp Res. 2005. https://pubmed.ncbi.nlm.nih.gov/15976520/
- Wessells H, Levine N, Hadley ME, et al. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.” Int J Impot Res. 2000. https://pubmed.ncbi.nlm.nih.gov/11035391/
- Montesinos J, Castilla-Ortega E, et al. “Activation of melanocortin-4 receptor inhibits both neuroinflammation induced by early exposure to ethanol and subsequent voluntary alcohol intake in adulthood: is BDNF the key mediator?” Front Cell Neurosci. 2020. https://pubmed.ncbi.nlm.nih.gov/32063838/
Disclaimer
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
